## Drug Summary
Phenazepam is a benzodiazepine drug, predominantly known for its use in the treatment of various neurological disorders such as epilepsy, alcohol withdrawal syndrome, and insomnia. Like other benzodiazepines, phenazepam works by enhancing the effect of the neurotransmitter GABA (gamma-aminobutyric acid) at the GABA_A receptor, leading to sedative, hypnotic, anxiolytic, anticonvulsant, and muscle relaxant properties. The pharmacokinetics of phenazepam involves absorption from the gastrointestinal tract, distribution throughout the body, and metabolism predominantly in the liver by cytochrome P450 enzymes. It is excreted mainly via the kidneys. Due to its high potency and long half-life, it is particularly susceptible to dosage accumulation and potential abuse.

## Drug Targets, Enzymes, Transporters, and Carriers
As indicated by general knowledge about benzodiazepines, phenazepam targets the GABA_A receptors to exert its effects. This receptor is a chloride channel that mediates the major inhibitory effects in the central nervous system. The enhancement of GABAergic activity leads to the therapeutic effects seen in conditions related to excessive neuronal excitation. In terms of metabolism, the drug is primarily processed in the liver. Various cytochrome P450 enzymes, commonly involved with other benzodiazepines, could be expected to participate in phenazepam's metabolism, though specific enzymes are not distinctly identified in the provided data.

## Pharmacogenetics
Pharmacogenetics studies of phenazepam are limited, but extrapolating from other well-studied benzodiazepines, genetic variations in the genes encoding the GABA_A receptor subunits or the cytochrome P450 enzymes might influence the drug's efficacy and safety. Certain alleles in genes like CYP2C19 or CYP3A4 can lead to variations in drug metabolism rates, impacting drug levels in the body and potentially leading to adverse effects or reduced efficacy. Memory impairment, increased sedation, and dependence may also vary by genetic makeup affecting the GABA_A receptor complexes. These interindividual differences highlight the need for personalized approaches in administering and managing treatment with phenazepam, although specific pharmacogenetic guidelines for phenazepam need more research and substantiation.